Get the Stockscreener App
13.53
1.42%
0.19
After Hours:
13.53
Pliant Therapeutics Inc stock is traded at $13.53, with a volume of 324.59K.
It is up +1.42% in the last 24 hours and down -4.38% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$13.34
Open:
$13.43
24h Volume:
324.59K
Relative Volume:
0.82
Market Cap:
$811.79M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-4.938
EPS:
-2.74
Net Cash Flow:
$-139.79M
1W Performance:
+6.28%
1M Performance:
-4.38%
6M Performance:
+6.28%
1Y Performance:
-4.58%
1-Day Range:
$13.14
$13.70
1-Week Range:
$12.52
$14.00
52-Week Range:
$10.22
$19.62
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
13.53 | 811.79M | 5.03M | -185.41M | -139.79M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
PLRXPliant Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Pliant Therapeutics, Inc. (NASDAQ:PLRX) is Great Point Partners LLC's 3rd Largest Position - MarketBeat
Pliant Therapeutics (STU:9PT) Change In Inventory : €0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail
Learn to Evaluate (PLRX) using the Charts - Stock Traders Daily
Atria Investments Inc Takes Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
PLRX (Pliant Therapeutics) Market Cap : $789.88 Mil (As of Nov. 24, 2024) - GuruFocus.com
PLRX (Pliant Therapeutics) Earnings Yield % : N/A% (As of Nov. 24, 2024) - GuruFocus.com
Pliant Therapeutics to Participate in Upcoming Investor Events - The Manila Times
Pliant Therapeutics to Present at 4 Major Healthcare Conferences in December | PLRX Stock News - StockTitan
Pliant Therapeutics Reports Increased Losses and Strategic Focus - TipRanks
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024 - GlobeNewswire
Pliant's Bexotegrast Shows Strong Phase 2 Results in Liver Disease Treatment Trial | PLRX Stock News - StockTitan
Redmile Group, LLC Adjusts Stake in Pliant Therapeutics Inc - GuruFocus.com
First Light Asset Management's Strategic Reduction in Pliant The - GuruFocus.com
Objective long/short (PLRX) Report - Stock Traders Daily
Pliant Therapeutics maintains stock target with Buy rating on clinical trial - Investing.com UK
Fresh Del Monte Produce (FDP-N) QuotePress Release - The Globe and Mail
Stifel maintains Buy on Pliant Therapeutics, target at $32 By Investing.com - Investing.com UK
HC Wainwright Reiterates "Buy" Rating for Pliant Therapeutics (NASDAQ:PLRX) - MarketBeat
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Pliant Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Possible Bearish Signals With Pliant Therapeutics Insiders Disposing Stock - Simply Wall St
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Harbor Capital Advisors Inc. - MarketBeat
Pliant Therapeutics to Participate in the Stifel Healthcare Conference - The Manila Times
Pliant Therapeutics to Present at Stifel 2024 Healthcare Conference | Key Leadership Insights | PLRX Stock News - StockTitan
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 5.4%Time to Sell? - MarketBeat
SG Americas Securities LLC Decreases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant reports positive Phase 2a trial results for liver disease drug - Investing.com Australia
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating - GlobeNewswire
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024 - Yahoo Finance
Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - US Post News
Pliant Therapeutics Inc’s Mixed Bag: Down -3.53% in 6 Months, Down 15.29% in 30 Days - The InvestChronicle
An Analysis of Pliant Therapeutics Inc (PLRX)’s Potential Price Growth - Knox Daily
The Manufacturers Life Insurance Company Purchases 1,191 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
How To Trade (PLRX) - Stock Traders Daily
Pliant Therapeutics (NASDAQ:PLRX) Trading 4.5% HigherStill a Buy? - MarketBeat
Pliant Therapeutics Inc [PLRX] Stock sold by Insider Lefebvre Eric for $0.14 million - Knox Daily
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Squarepoint Ops LLC Takes $865,000 Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Algert Global LLC Increases Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - MarketBeat
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc - Yahoo Finance
Pliant Therapeutics stock hits 52-week low at $10.24 - Investing.com
Pliant Therapeutics appoints new SVP of Medical Affairs - Investing.com India
Pliant Therapeutics stock hits 52-week low at $10.24 By Investing.com - Investing.com Australia
Pliant Therapeutics (NASDAQ:PLRX) Sets New 12-Month Low at $10.24 - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Hits New 1-Year Low at $10.24 - Defense World
Investor’s Toolkit: Key Ratios for Assessing Pliant Therapeutics Inc (PLRX)’s Performance - The Dwinnex
American Century Companies Inc. Has $797,000 Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pliant Therapeutics Inc Stock (PLRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hull Hans | Chief Business Officer |
Jul 10 '24 |
Sale |
11.56 |
9,900 |
114,444 |
227,494 |
| Cummings Keith Lamont | Chief Financial Officer |
Jul 10 '24 |
Sale |
11.56 |
10,911 |
126,131 |
282,115 |
| Coulie Bernard | President and CEO |
Jul 10 '24 |
Sale |
11.56 |
38,710 |
447,488 |
482,936 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jul 10 '24 |
Sale |
11.56 |
7,656 |
88,503 |
94,044 |
| Cummings Keith Lamont | Chief Financial Officer |
May 02 '24 |
Option Exercise |
2.08 |
21,000 |
43,680 |
271,713 |
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '24 |
Sale |
17.23 |
9,781 |
168,527 |
194,605 |
| Hull Hans | Chief Business Officer |
Jan 17 '24 |
Sale |
17.23 |
9,786 |
168,613 |
185,069 |
| Coulie Bernard | President and CEO |
Jan 17 '24 |
Sale |
17.23 |
25,721 |
443,173 |
316,382 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '24 |
Sale |
17.23 |
10,295 |
177,383 |
156,920 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '24 |
Sale |
17.23 |
5,197 |
89,544 |
55,246 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):